A quiet revolution is coming to CDMOs - it’s driven by data and it will decide who wins the next decade.

A quiet revolution is coming to CDMOs - it’s driven by data and it will decide who wins the next decade.

Over the next five years, Contract Development and Manufacturing Organizations (CDMOs) around the world will undergo a major transformation in how they develop and deliver processes.

Until now, they have mostly competed on capacity, quality, and regulatory track record. But by 2030, the defining metric will be how fast they can learn.

How many CDMOs today truly learn from the huge amounts of data and knowledge they’ve accumulated over decades?

AI is no longer a futuristic add-on; it is becoming the core of process development and manufacturing. An internal AI function will soon be as essential as a QC or analytical department.

Every experiment, batch record, and deviation log holds valuable learnings. CDMOs that can convert these data into predictive models will continuously improve performance and protect their competitive edge. 

At the same time, pharmaceutical companies are beginning to expect their external partners to operate on the same data level - to build models, run simulations, and interpret outcomes before an experiment starts.

We’re already seeing pharma companies sharing structured, machine-readable datasets - not just static protocols - with their CDMO partners. 

This shift enables process knowledge and experimental context to flow seamlessly between organizations, reducing redundant lab work and accelerating tech transfer from development to manufacturing.

But with that level of connectivity comes a new challenge: how can CDMOs leverage these learning effects across projects without risking compliance or confidentiality when working with multiple clients, sometimes in competing fields?

Balancing collective intelligence with strict data integrity will define the winners of the next decade.

‍